会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明专利
    • Hemostatic material
    • HEMOSTATIC MATERIAL
    • JP2005074079A
    • 2005-03-24
    • JP2003310129
    • 2003-09-02
    • Chemo Sero Therapeut Res InstMasao Tanihara正夫 谷原財団法人化学及血清療法研究所
    • TANIHARA MASAOKINOSHITA HISAOIMAMURA TAKAYUKINOZAKI CHIKAHIDE
    • A61K47/34A61K38/48A61K47/36A61K47/42A61L15/44A61P7/04
    • PROBLEM TO BE SOLVED: To provide a hemostatic material which is excellent in a hemostatic effect, in vivo decomposing and absorbing property, uniformity in quality, and stability, and which reduces the risk of mixing an animal-derived pathogen.
      SOLUTION: This hemostatic material contains thrombin and a synthetic polypeptide which can form a tri-helix structure. The molecular weight of the polypeptide can indicate a peak in the range of 5×10
      4 -100×10
      4 . The polypeptide may contain a peptide unit expressed at least by the formula, Pro-X-Gly (X indicates Pro or Hyp (hydroxyproline) in the formula). Thrombin can be a recombinant. The rate of thrombin can be a degree of 0.1-500 unit (U) with respect to the polypeptide in the hemostatic material. A binder component having in vivo decomposing and absorbing property can be contained in the hemostatic material. The material can be formed on a base material.
      COPYRIGHT: (C)2005,JPO&NCIPI
    • 要解决的问题:提供止血效果优异,体内分解吸收性,质量均匀性和稳定性优异的止血材料,降低动物来源病原体的混合风险。 解决方案:该止血材料含有可以形成三螺旋结构的凝血酶和合成多肽。 多肽的分子量可以表示在5×10 -4 / SP> -100×10 4 的范围内的峰。 多肽可以含有至少由下式表示的肽单元,Pro-X-Gly(X表示式中的Pro或Hyp(羟基脯氨酸))。 凝血酶可以是重组体。 关于止血材料中的多肽,凝血酶的比例可以是0.1-500单位(U)的程度。 在止血材料中可以含有具有体内分解吸收性的粘合剂成分。 该材料可以形成在基材上。 版权所有(C)2005,JPO&NCIPI
    • 8. 发明专利
    • Method for manufacturing package of freeze-dried medicine
    • 冷冻干燥药物包装方法
    • JP2010124931A
    • 2010-06-10
    • JP2008300741
    • 2008-11-26
    • Chemo Sero Therapeut Res InstKanae Co Ltd株式会社カナエ財団法人化学及血清療法研究所
    • IMAMURA TAKAYUKIOWAKI HITOMIMAEDA HIROAKIAKIMURA YASUNORI
    • A61J3/00A61J1/03F26B5/06
    • F26B5/06
    • PROBLEM TO BE SOLVED: To provide a method for manufacturing the sterile package of a freeze-dried medicine without requiring a large amount of equipment investment to keep sterile property nor having the risk of deformation or deactivation when the medicine is protein, etc., concerning the method for manufacturing the package of the freeze-dried medicine with the sterile property kept therein. SOLUTION: The method includes the following processes (1) to (3), i.e., (1) the process for storing the medicine to be freeze-dried in a container under the sterile property, (2) the process for allowing a sealed sheet with bacteria-blocking property and ventilation to be welded onto the peripheral edge of the container with the medicine stored therein under the sterile property, and (3) the process for freeze-drying the container which is sealed after welding the sealed sheet onto the peripheral edge of the container. COPYRIGHT: (C)2010,JPO&INPIT
    • 要解决的问题:提供一种用于制造冷冻干燥药物的无菌包装的方法,而不需要大量的设备投资来保持无菌性质,当药物是蛋白质等时,也不具有变形或失活的风险。 关于制造具有保存在其中的无菌性质的冷冻干燥药物包装的方法。 解决方案:该方法包括以下(1)至(3)的方法,即(1)在无菌性质下将容器中的待冷冻干燥药物储存的方法,(2)允许的方法 具有细菌阻隔性的密封片材和通气,其中药物在无菌性质下存储在容器的周边边缘上,以及(3)在将密封片材焊接之后密封的容器的冷冻干燥方法 到容器的外围边缘。 版权所有(C)2010,JPO&INPIT